ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1728

Purified IgG From Antiphospholipid Syndrome Patients with Pregnancy Morbidity Alone Inhibit Trophoblast Migration and Activate a TLR4 MyD88 Independent Pathway

Katie Poulton1, Vera Ripoll1, Charis Pericleous2, Yiannis Ioannou3, Anisur Rahman4 and Ian Giles4, 1Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, 2Centre for Rheumatology, Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom, 3Arthritis Research UK Centre for Adolescent Rheumatology at University College London, Great Ormond Street Hospital and UCLH, University College London, London, United Kingdom, 4Centre for Rheumatology Research,Rayne Institute, 4th Floor, University College London, London, United Kingdom

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: antiphospholipid syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Antiphospholipid Syndrome

Session Type: Abstract Submissions (ACR)

Background/Purpose: Patients with the Antiphospholipid Syndrome (APS) have circulating antiphospholipid antibodies which cause vascular thrombosis (VT) and/or pregnancy morbidity (PM). Previously we have shown that IgG isolated from patients with APS-VT alone caused activation of p38MAPK and NFκB signalling pathways and up-regulation of tissue factor activity in monocytes. These effects were not seen with IgG from patients with APS-PM alone or healthy controls. TF up-regulation caused by the APS-VT samples was reduced by p38MAPK, NFκB, and TLR4 inhibitors, thus implicating a TLR4-MyD88 dependent signalling mechanism (J Immunol, 2010;184:6622). Therefore, in this study we examine whether IgG isolated from patients with different manifestations of the APS have differential effects upon similar pathways leading to activation and migration of trophoblast cells which are more relevant to PM.

Methods: IgG was isolated by protein G purification from serum of 5 patients with APS and VT alone (IgG-VT), 5 patients with APS and PM alone (IgG-PM) and 5 healthy controls. To investigate the intracellular signalling pathways induced by these IgG, a single sample for each of the 3 groups was produced by pooling IgG from the 5 subjects in that group. A human first trimester trophoblast (HTR-8) cell line was incubated with 100 μg/mL IgG from each group. Time course experiments were then performed and mRNA expression of TLR4 and related adaptor protein TRIF was measured using quantitative PCR. The activation of p38MAPK, ERK and NFκB signalling pathways was also examined in cell extracts by immunoblot. Trophoblast migration was determined using a collagen-based cell invasion assay.

Results: Only IgG-PM increased TLR4 mRNA expression (at 6 and 24 hours) and TLR4 (non-MyD88 dependent) adaptor protein TRIF mRNA levels (at 6 hours) compared with IgG-VT and healthy control IgG in HTR-8 cells. None of the APS (VT or PM)-IgG however, increased phosphorylation of TLR4-MyD88 dependent p38MAPK, ERK or NFκB signalling pathways at any (15 minutes, 2 and 6 hour) time points measured in these cells compared with control IgG. IgG-PM caused the greatest inhibition of trophoblast (HTR-8) migration (with 27% inhibition) compared to untreated controls at 48 hours. In contrast, IgG-VT caused minimal (8%) inhibition of trophoblast migration comparable to levels seen with healthy control IgG.

Conclusion: IgG isolated from patients with APS-related PM preferentially inhibit trophoblast cell migration compared with APS-IgG from patients with VT alone. IgG isolated from patients with APS-related PM also activate trophoblast cells via a TLR4 MyD88 independent pathway. This is the reverse of our previous finding in monocytes that were only activated by APS-IgG from patients with VT and not from those with PM. Further experiments are now required to characterise the mechanistic and prognostic implications of these findings.


Disclosure:

K. Poulton,
None;

V. Ripoll,
None;

C. Pericleous,
None;

Y. Ioannou,
None;

A. Rahman,
None;

I. Giles,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/purified-igg-from-antiphospholipid-syndrome-patients-with-pregnancy-morbidity-alone-inhibit-trophoblast-migration-and-activate-a-tlr4-myd88-independent-pathway/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology